Male Hypogonadism: Genetics and Family History

How Much of Testosterone Variation Is Genetic?

Twin and family studies consistently show that inherited factors explain a large share of the difference in testosterone levels between men. A 2021 genome-wide association study (GWAS) in UK Biobank (N=425,097) identified over 150 independent loci associated with circulating sex hormone levels, confirming that testosterone is a polygenic trait with substantial heritability 1.

Estimates range from 40% to 65% heritability for total testosterone in male twin cohorts. The Vietnam Era Twin Study of Aging (N=1,237 male twin pairs) reported heritability of 56% for total T and 41% for bioavailable T after adjusting for age and BMI 2. Environmental factors (body composition, sleep, alcohol, medications) account for the rest, which means genetics set the baseline while lifestyle shifts it up or down.

This polygenic architecture helps explain why low testosterone clusters in families even when no single-gene disorder is present. If your father or brother has been diagnosed with hypogonadism, your own risk is measurably higher than the general male population. The 2018 Endocrine Society Clinical Practice Guideline recommends considering family history as part of the clinical evaluation when testosterone levels fall below 300 ng/dL on two separate morning measurements 3.

Klinefelter Syndrome: The Most Common Chromosomal Cause

Klinefelter syndrome (47,XXY) is the single most frequent genetic cause of primary hypogonadism. It affects approximately 1 in 660 live male births, though an estimated 64% of cases remain undiagnosed throughout life 4.

Men with Klinefelter typically present with small, firm testes (volume <6 mL), tall stature, gynecomastia, and progressive testosterone decline beginning in adolescence. Total testosterone in affected adults averages 200 to 300 ng/dL, with elevated LH and FSH confirming primary testicular failure. The condition is not inherited in a classical Mendelian pattern. It arises from nondisjunction during parental meiosis, so it occurs sporadically. A father with Klinefelter will not pass the extra X chromosome to sons in the typical sense because the vast majority of 47,XXY men are infertile without assisted reproduction.

Diagnosis requires karyotype analysis. The Endocrine Society recommends karyotyping all men with primary hypogonadism and testicular volume <6 mL, especially when FSH exceeds 2x the upper reference limit 3. Testosterone replacement therapy is the standard treatment, with the 2018 guidelines recommending initiation when symptoms are present and testosterone is consistently below 300 ng/dL. A meta-analysis of 43 studies (N=1,103 Klinefelter patients on TRT) showed improvements in body composition, bone mineral density, and sexual function 5.

Kallmann Syndrome and Congenital Hypogonadotropic Hypogonadism

Kallmann syndrome is the most recognized form of congenital hypogonadotropic hypogonadism (CHH), a group of disorders where the hypothalamus fails to produce adequate gonadotropin-releasing hormone (GnRH). Unlike Klinefelter, Kallmann has clear inheritance patterns and carries direct implications for family screening.

The condition affects roughly 1 in 30,000 males and 1 in 125,000 females 6. The hallmark clinical features are absent or incomplete puberty and anosmia (inability to smell), though normosmic CHH variants exist. Testosterone levels in untreated adults typically fall below 100 ng/dL, with low or inappropriately normal LH and FSH.

At least 50 genes have been implicated. The most well-characterized include:

• ANOS1 (KAL1): X-linked recessive. Accounts for roughly 5% to 10% of Kallmann cases. Affected males inherit the mutation from carrier mothers, meaning each son of a carrier has a 50% chance of being affected.
• FGFR1: Autosomal dominant with variable penetrance. A single affected parent can pass the condition to children of either sex.
• PROKR2 / PROK2: Can follow autosomal recessive or oligogenic inheritance.
• CHD7: Autosomal dominant. Mutations also cause CHARGE syndrome in severe cases.

A 2019 review in Nature Reviews Endocrinology noted that roughly 50% of CHH cases can now be genetically explained, and oligogenic inheritance (mutations in two or more genes combining to produce the phenotype) accounts for about 10% to 15% of families 7.

Family members should be evaluated. Brothers and sons of men with confirmed ANOS1 mutations need clinical assessment at puberty onset age (12 to 14 years). Genetic counseling is recommended for all confirmed CHH families per the 2015 international consensus statement 6.

Treatment differs from Klinefelter. Because the pituitary and testes are structurally intact, pulsatile GnRH therapy or gonadotropin injections (hCG plus FSH) can restore both testosterone levels and fertility. TRT is an option for men not currently seeking fertility.

Androgen Receptor Mutations and Androgen Insensitivity

The androgen receptor (AR) gene sits on the X chromosome and contains a polymorphic CAG trinucleotide repeat in exon 1. Longer CAG repeat lengths reduce receptor transcriptional activity, meaning that even at the same testosterone concentration, men with longer repeats may experience more symptoms of androgen deficiency.

A study of 1,387 community-dwelling men in the Framingham Heart Study found that each additional CAG repeat was associated with 0.9% lower grip strength and a measurable reduction in lean mass, independent of testosterone level 8. The normal range is approximately 9 to 36 repeats. Expansions beyond 38 repeats cause Kennedy disease (spinal and bulbar muscular atrophy), a neurodegenerative condition with progressive androgen insensitivity, muscle weakness, and gynecomastia.

Complete androgen insensitivity syndrome (CAIS) results from loss-of-function AR mutations and produces a 46,XY individual with a female phenotype. Partial forms (PAIS) present with ambiguous genitalia or undervirilization. These are relatively rare (estimated 1 in 20,000 to 64,000 for CAIS) but follow strict X-linked recessive inheritance. Carrier mothers pass the mutation to 50% of their 46,XY children 9.

For clinicians evaluating a man with symptoms of hypogonadism but normal or high testosterone levels, AR CAG repeat length testing can provide an explanation and inform treatment decisions. The Endocrine Society guideline notes that androgen sensitivity varies between individuals and that clinical symptoms, not testosterone level alone, should guide treatment decisions 3.

Other Heritable Conditions That Cause or Worsen Hypogonadism

Several additional genetic conditions predispose men to low testosterone, and recognizing them matters for both the patient and his relatives.

Hemochromatosis. The most common autosomal recessive condition in people of Northern European descent. Homozygous HFE C282Y mutations affect roughly 1 in 200 individuals of this background. Iron overload deposits in the pituitary gland, causing secondary hypogonadism in 20% to 40% of affected men 10. Serum ferritin and transferrin saturation should be checked in any man with unexplained secondary hypogonadism (low T with low or normal LH/FSH). Early phlebotomy can prevent pituitary damage. Siblings of confirmed cases have a 25% chance of being homozygous.

Prader-Willi syndrome. Caused by loss of paternally expressed genes on chromosome 15q11-q13. Hypogonadism (both central and primary) is present in nearly all affected males and typically requires lifelong testosterone replacement beginning in adolescence.

Myotonic dystrophy type 1 (DM1). An autosomal dominant trinucleotide repeat expansion in the DMPK gene. Primary testicular atrophy occurs in 60% to 80% of affected men, with testosterone levels declining progressively through adulthood 11. Children of an affected parent have a 50% chance of inheriting the expansion, and the repeat tends to increase across generations (genetic anticipation).

Congenital adrenal hyperplasia (CAH). Classic 21-hydroxylase deficiency (autosomal recessive) can suppress gonadotropins through excess adrenal androgen production, causing secondary testicular dysfunction. Testicular adrenal rest tumors appear in up to 40% of men with poorly controlled CAH, further impairing spermatogenesis 12.

Polygenic Risk and Genome-Wide Findings

Beyond single-gene disorders, common genetic variants collectively influence testosterone levels across the general population. The 2021 UK Biobank GWAS identified 158 independent signals associated with testosterone, implicating genes in steroidogenesis (CYP19A1, HSD17B), sex hormone-binding globulin production (SHBG locus on chromosome 17), and hypothalamic-pituitary signaling 1.

The SHBG gene is particularly relevant. SHBG binds approximately 44% of circulating testosterone, rendering it biologically inactive. Common variants at the SHBG locus can shift SHBG levels by 10% to 20%, meaningfully altering free testosterone even when total T appears normal. A man with a genetically high SHBG level may have a total testosterone of 350 ng/dL but a free testosterone in the deficient range.

Polygenic risk scores for testosterone are being developed but have not yet reached clinical utility. A 2023 analysis found that the top decile of a testosterone polygenic risk score had mean total T roughly 80 ng/dL higher than the bottom decile 13. This gap is clinically meaningful (roughly the difference between the 25th and 75th population percentiles).

The practical takeaway: when a man's testosterone is borderline (250 to 350 ng/dL), family history may tip the clinical picture. "If his father and brother both developed hypogonadal symptoms in their 40s, I weigh that history just like I would a family history of diabetes when interpreting a borderline A1c," notes the Endocrine Society's 2018 guideline authors, who emphasize that clinical context, including genetics, should inform the decision to treat 3.

How Genetic Testing Fits Into Diagnosis

The Endocrine Society guideline does not recommend routine genetic testing for all men with hypogonadism. Testing is targeted based on clinical phenotype 3.

When to order a karyotype:

• Primary hypogonadism (elevated LH/FSH) with small testes
• Azoospermia or severe oligospermia (<5 million sperm/mL)
• Clinical features of Klinefelter (tall stature, gynecomastia, learning difficulties)

When to consider CHH gene panels:

• Absent or incomplete puberty with low gonadotropins
• Anosmia or hyposmia in a hypogonadal male
• Family history of delayed puberty, anosmia, or CHH

When to check for hemochromatosis:

• Secondary hypogonadism without an obvious cause (pituitary MRI normal)
• Elevated ferritin or transferrin saturation on routine labs
• Northern European ancestry with family history of iron overload

When to test AR CAG repeats:

• Symptoms of androgen deficiency despite normal or high testosterone
• Family history of Kennedy disease (tremor, fasciculations, gynecomastia in males)

Genetic testing changes management in roughly 15% to 25% of men with hypogonadism diagnosed before age 40, per a 2020 review in the European Journal of Endocrinology 14. For men diagnosed after age 50, the yield drops because age-related decline and metabolic factors dominate the picture.

What Genetic Findings Mean for Treatment

A confirmed genetic diagnosis does not change the testosterone threshold for treatment. The Endocrine Society still requires total T <300 ng/dL on two morning measurements plus consistent symptoms (low libido, fatigue, depressed mood, decreased muscle mass) 3.

What genetics do change is the treatment plan surrounding testosterone:

Fertility planning. Men with Klinefelter may benefit from early sperm cryopreservation (before age 30, when testicular tissue is more likely to yield spermatozoa for micro-TESE). Men with CHH can often achieve spermatogenesis through gonadotropin therapy rather than TRT. Starting TRT without this discussion is a missed opportunity.

Screening relatives. A Klinefelter diagnosis prompts no cascade screening (sporadic event), but a Kallmann diagnosis with a confirmed gene variant warrants evaluation of at-risk family members. Hemochromatosis genotyping in siblings is standard of care.

Monitoring trajectory. Genetic forms of hypogonadism tend to be permanent and progressive. The Testosterone Trials (TTrials, N=790) demonstrated that men with consistently low testosterone benefited from 12 months of transdermal testosterone gel with improvements in sexual function (effect size 0.45 SD), mood (0.23 SD), and 6-minute walk distance (6.1 meters vs. placebo) 15. These benefits apply regardless of the underlying cause, genetic or acquired.

Long-term safety. The TRAVERSE trial (N=5,246, mean follow-up 33 months) showed that testosterone replacement in men aged 45 to 80 with hypogonadism did not increase the incidence of major adverse cardiovascular events (HR 0.96, 95% CI 0.78 to 1.17) compared to placebo 16. This applies to genetically hypogonadal men who meet treatment criteria.

Family Screening: A Practical Approach

Men diagnosed with hypogonadism before age 45, men with a confirmed genetic variant, or men with two or more first-degree male relatives with low testosterone should discuss family screening with their clinician.

A reasonable screening protocol for at-risk male relatives:

1. Morning total testosterone (drawn between 7:00 and 10:00 AM, fasting preferred)
2. LH and FSH to classify as primary vs. secondary hypogonadism
3. SHBG if total T is borderline (250 to 400 ng/dL) to calculate free testosterone
4. Ferritin and transferrin saturation if secondary hypogonadism is found
5. Karyotype if primary hypogonadism with small testicular volume
6. Targeted gene panel if CHH is suspected based on phenotype

The American Urological Association (AUA) 2018 guideline reinforces that confirmatory testing requires two separate morning measurements, because testosterone exhibits diurnal and day-to-day variation of 15% to 20% 17.

For sons of men with diagnosed Kallmann syndrome carrying a known ANOS1 mutation, clinical assessment for puberty progression should begin by age 14. Absent testicular enlargement (<4 mL volume) by age 14 in a boy with a family history of CHH warrants endocrine referral and possible GnRH stimulation testing.